¹⁸F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study

References

• Swerdlow SH, Campo E, Harris NL, et al. World health organization classification of tumours. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed, Revised. Lyon (France): International Agency for Research on Cancer; 2017. p. 403–422. (Bosman FT, Jaffe ES, Lakhani SR, eds.).
   Google Scholar
• Armitage JO. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol. 2017 Jul;92(7):706–715. doi: 10.1002/ajh.24791
   PubMed Web of Science ®Google Scholar
• Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des lymphomes agressives). Ann Oncol. 1990;1(1):45–50. doi: 10.1093/oxfordjournals.annonc.a057673
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008 Sep 1;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• d’Amore F, Gaulard P, Trümper L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v108–15.
   PubMedGoogle Scholar
• Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade Non-Hodgkin lymphoma study group. Blood. 2010 Nov 4;116(18):3418–3425. doi: 10.1182/blood-2010-02-270785
   PubMed Web of Science ®Google Scholar
• Cottereau AS, Becker S, Broussais F, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016 Apr;27(4):719–724.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004 Apr 1;103(7):2474–2479. doi: 10.1182/blood-2003-09-3080
   PubMed Web of Science ®Google Scholar
• Gutiérrez-García G, García-Herrera A, Cardesa T, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011 Feb;22(2):397–404.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Habermann TM, Kurtin PJ, et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol. 1997 Jun;15(6):2296–2301.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059–3067. doi: 10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014 Sep 20;32(27):3048–3058. doi: 10.1200/JCO.2013.53.5229
   PubMed Web of Science ®Google Scholar
• Badr S, Kotb M, Elahmadawy MA, et al. Predictive value of FDG PET/CT versus bone marrow biopsy in pediatric lymphoma. Clin Nucl Med. 2018 Dec;43(12):e428–e438.
   PubMed Web of Science ®Google Scholar
• Moulin-Romsee G, Hindie E, Cuenca X, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1095–1105.
   PubMed Web of Science ®Google Scholar
• El-Galaly TC, d’Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012 Dec 20;30(36):4508–4514. doi: 10.1200/JCO.2012.42.4036
   PubMed Web of Science ®Google Scholar
• Hassan A, Siddique M, Bashir H, et al. (18)F-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin’s lymphoma: a quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement. Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1198–1206.
   PubMed Web of Science ®Google Scholar
• Voltin CA, Goergen H, Baues C, et al. Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Ann Oncol. 2018 Sep 1;29(9):1926–1931. doi: 10.1093/annonc/mdy250
   PubMed Web of Science ®Google Scholar
• Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013 Aug;54(8):1244–1250.
   PubMed Web of Science ®Google Scholar
• Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013 Jul 4;122(1):61–67. doi: 10.1182/blood-2012-12-473389
   PubMed Web of Science ®Google Scholar
• Adams HJ, Kwee TC, de Keizer B, et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):565–574.
   PubMed Web of Science ®Google Scholar
• Adams HJ, Kwee TC, Fijnheer R, et al. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol. 2014 Jul;89(7):726–731.
   PubMed Web of Science ®Google Scholar
• Alzahrani M, El-Galaly TC, Hutchings M, et al. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study. Ann Oncol. 2016 Jun;27(6):1095–1099.
   PubMed Web of Science ®Google Scholar
• Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003 May 15;101(10):3875–3876. doi: 10.1182/blood-2002-09-2778
   PubMed Web of Science ®Google Scholar
• Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007 Oct;18(10):1685–1690.
   PubMed Web of Science ®Google Scholar
• Lee Y, Hwang KH, Hong J, et al. Usefulness of (18)F-FDG PET/CT for the evaluation of bone marrow involvement in patients with high-grade non-Hodgkin’s lymphoma. Nucl Med Mol Imaging. 2012 Dec;46(4):269–277.
   PubMedGoogle Scholar
• Pham AQ, Broski SM, Habermann TM, et al. Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue. Leuk Lymphoma. 2017 Oct;58(10):2342–2348.
   PubMed Web of Science ®Google Scholar
• Gurion R, Bernstine H, Domachevsky L, et al. Utility of PET-CT for evaluation of patients with peripheral T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):687–691.
   PubMed Web of Science ®Google Scholar
• Koh Y, Lee JM, Woo GU, et al. FDG PET for evaluation of bone marrow status in T-cell lymphoma. Clin Nucl Med. 2019 Jan;44(1):4–10.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang X, Qin H, et al. Prognostic values of baseline (18)F-FDG PET/CT in patients with peripheral T-cell lymphoma. Biomed Res Int. 2020;2020:9746716. doi: 10.1155/2020/9746716
   PubMed Web of Science ®Google Scholar
• El-Galaly TC, Pedersen MB, Hutchings M, et al. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: a review of 124 patients. Am J Hematol. 2015 Nov;90(11):975–980.
   PubMed Web of Science ®Google Scholar
• Ham JS, Kim SJ, Choi JY, et al. The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma. Blood Cancer J. 2016 Feb 12;6(2):e395. doi: 10.1038/bcj.2016.2
   PubMedGoogle Scholar
• Tomita N, Hattori Y, Fujisawa S, et al. Post-therapy (1)(8)F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma. Ann Hematol. 2015 Mar;94(3):431–436.
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Argnani L, Broccoli A, et al. Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. Oncology. 2014 Jul;19(7):746–750.
   Google Scholar
• Jung SH, Ahn JS, Kim YK, et al. Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. BMC Cancer. 2015 Mar 28;15(1):198. doi: 10.1186/s12885-015-1193-1
   PubMedGoogle Scholar
• Rodríguez-Pinilla SM, Domingo-Domènech E, Climent F, et al. Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study. Br J Haematol. 2021 Jan;192(1):82–99.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Meignan M, et al. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009 Aug;50(8):1257–1260.
   PubMed Web of Science ®Google Scholar
• Van Heertum RL, Scarimbolo R, Wolodzko JG, et al. Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials. Drug Des Devel Ther. 2017;11:1719–1728. doi: 10.2147/DDDT.S136988
   PubMed Web of Science ®Google Scholar
• Ahn SY, Jung SY, Jung SH, et al. Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas. Ann Hematol. 2020 Jan;99(1):83–91.
   PubMed Web of Science ®Google Scholar
• Abe Y, Kitadate A, Usui Y, et al. Diagnostic and prognostic value of using 18F-FDG PET/CT for the evaluation of bone marrow involvement in peripheral T-cell lymphoma. Clin Nucl Med. 2019 May;44(5):e336–e341.
   PubMed Web of Science ®Google Scholar
• Cottereau AS, El-Galaly TC, Becker S, et al. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients. J Nucl Med. 2018 Apr;59(4):589–595.
   PubMed Web of Science ®Google Scholar